Analysts Offer Predictions for PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Palvella Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($1.60) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research report on Friday, January 10th.

Palvella Therapeutics Trading Down 3.8 %

NASDAQ:PVLA opened at $12.49 on Thursday. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The company has a market cap of $16.49 million, a price-to-earnings ratio of -1.03 and a beta of 0.67.

Insider Buying and Selling

In other Palvella Therapeutics news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares in the company, valued at $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.39% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.